Results 81 to 90 of about 9,742,950 (352)

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

A tool for facilitating OCR postediting in historical documents [PDF]

open access: yes, 2020
Optical character recognition (OCR) for historical documents is a complex procedure subject to a unique set of material issues, including inconsistencies in typefaces and low quality scanning. Consequently, even the most sophisticated OCR engines produce
Aboomar, Mohammad   +4 more
core   +1 more source

Speech and hand transcribed retrieval [PDF]

open access: yes, 2002
This paper describes the issues and preliminary work involved in the creation of an information retrieval system that will manage the retrieval from collections composed of both speech recognised and ordinary text documents.
Sanderson, M., Shou, X.M.
core   +3 more sources

A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer

open access: yesMolecular Oncology, Volume 19, Issue 12, Page 3634-3650, December 2025.
Gene expression meta‐analysis in multiple prostate cancer patient cohorts identifies Transcription factor 19 (TCF19) as an aggressiveness‐sustaining gene with prognostic potential. TCF19 is a gene repressed by androgen signaling that sustains core cancer‐related processes such as vascular permeability or tumor growth and metastasis.
Amaia Ercilla   +15 more
wiley   +1 more source

Categorization Schemes in Web of Science CC

open access: yesInformaciâ i Innovacii, 2018
The article presents the analysis of the two classification schemes that are integrated in Web of Science Core Collection - the “Web of Science Categories” and “Research Areas”.
Yu. V. Mokhnacheva
doaj   +1 more source

Multi‐omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma

open access: yesMolecular Oncology, Volume 19, Issue 12, Page 3806-3820, December 2025.
Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf   +10 more
wiley   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Visualizing the Intellectual Structure of Iranian Physicists in Scisearch during 1990-2009: An Author Co-Citation Analysis (ACA)

open access: yesInternational Journal of Information Science and Management, 2012
The purpose of this paper was to study and map the intellectual structure of Iranian physicists using author co-citation technique during 1990-2009.
F. Osareh, R. Khademi
doaj  

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy